German patients challenging the recent controversial changes to medical cannabis reimbursement via statutory health insurance (GKV) are facing lengthy battles across the country’s courts.
Germany’s coalition government has retreated further on its controversial medical cannabis reimbursement reforms as it faces mounting questions over how and why the law came to be.
James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation and more controlled delivery could help realise it.
Is cannabis legal in Germany? No, not in the way it is in the majority of US states or Canada.
Last month, the German government passed a controversial cost-saving law that saw tens of thousands of patients denied access medical cannabis to flower reimbursed through statutory health insurance (GKV).
Written by Michael Sassano, Founder and Interim CEO, SOMAÍ Pharmaceuticals Most US cannabis companies thinking about Europe focus on the wrong number.
Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.
Germany’s Cannabis Act (CanG) has not led to an increase in use among young people, according to new peer-reviewed research adding to the growing body of evidence contradicting the harms predicted by the reform’s critics.
Germany has today voted to ban medical cannabis flower from its statutory health insurance scheme, in a controversial move critics say will have an outsized impact on the ‘seriously ill’.
